Cardiff Oncology, Inc. (FRA:XE7C)

Market Cap	92.05M -68.8%
Revenue (ttm)	427.00K -27.2%
Net Income	-43.00M
EPS	-0.68
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	542
Open	1.308
Previous Close	1.344
Day's Range	1.308 - 1.308
52-Week Range	1.180 - 4.565
Beta	n/a
RSI	39.96
Earnings Date	Feb 27, 2026

About Cardiff Oncology

Cardiff Oncology, Inc., a clinical-stage biotechnology company, develops novel therapies for the treatment of various cancers. Its lead drug candidate is Onvansertib, an oral and selective polo-like kinase 1 inhibitor for treating RAS-mutated metastatic colorectal cancer. The company also focuses on the clinical program in indications, such as investigator-initiated ongoing or planned trials in metastatic pancreatic ductal adenocarcinoma, small cell lung cancer, and triple negative breast cancer; CRDF-004, a Phase 2 open-label randomized multi-...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 1999
• Employees: 33
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: XE7C

Financial Performance

In 2024, Cardiff Oncology's revenue was $683,000, an increase of 39.96% compared to the previous year's $488,000. Losses were -$45.46 million, 9.62% more than in 2023.

Financial numbers in USD